Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity
Yan Xiong, … , Philip A. Cole, Wayne W. Hancock
Yan Xiong, … , Philip A. Cole, Wayne W. Hancock
Published January 9, 2020
Citation Information: J Clin Invest. 2020;130(4):1830-1842. https://doi.org/10.1172/JCI131375.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 9

Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity

  • Text
  • PDF
Abstract

Foxp3+ Tregs are key to immune homeostasis, but the contributions of various large, multiprotein complexes that regulate gene expression remain unexplored. We analyzed the role in Tregs of the evolutionarily conserved CoREST complex, consisting of a scaffolding protein, Rcor1 or Rcor2, plus Hdac1 or Hdac2 and Lsd1 enzymes. Rcor1, Rcor2, and Lsd1 were physically associated with Foxp3, and mice with conditional deletion of Rcor1 in Foxp3+ Tregs had decreased proportions of Tregs in peripheral lymphoid tissues and increased Treg expression of IL-2 and IFN-γ compared with what was found in WT cells. Mice with conditional deletion of the gene encoding Rcor1 in their Tregs had reduced suppression of homeostatic proliferation, inability to maintain long-term allograft survival despite costimulation blockade, and enhanced antitumor immunity in syngeneic models. Comparable findings were seen in WT mice treated with CoREST complex bivalent inhibitors, which also altered the phenotype of human Tregs and impaired their suppressive function. Our data point to the potential for therapeutic modulation of Treg functions by pharmacologic targeting of enzymatic components of the CoREST complex and contribute to an understanding of the biochemical and molecular mechanisms by which Foxp3 represses large gene sets and maintains the unique properties of this key immune cell.

Authors

Yan Xiong, Liqing Wang, Eros Di Giorgio, Tatiana Akimova, Ulf H. Beier, Rongxiang Han, Matteo Trevisanut, Jay H. Kalin, Philip A. Cole, Wayne W. Hancock

×

Figure 2

Cellular effects of Rcor1 deletion in Foxp3+ Tregs.

Options: View larger image (or click on image) Download as PowerPoint
Cellular effects of Rcor1 deletion in Foxp3+ Tregs.
(A) Percentages of C...
(A) Percentages of CD4+Foxp3+ Tregs in lymph nodes, spleens, and thymi of WT and Rcor1–/– mice, shown as representative plots (left) and with statistical analyses (right). (B) T cell activation markers in CD4+ and CD8+ T cells of WT and Rcor1−/− mice were analyzed as percentages of gated cells; data shown are representative of 4 to 6 experiments (left). Statistical analyses are shown (right). In (A) and (B) data are shown as mean ± SD, 6 to 8 mice/group. Student’s t test for unpaired data. *P < 0.05 vs. WT control. (C) Treg suppression assays were performed using pooled (4 mice/group) Tregs and Teff cells from lymph nodes and spleens of WT and Rcor1–/– mice, as indicated. Assays were run in triplicate and repeated at least 3 times. The results of a representative experiment are shown, along with the percentages of proliferating cells in each panel.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
Referenced in 2 patents
On 2 Facebook pages
57 readers on Mendeley
See more details